noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Pharmaceuticals and Biotechnology

Altimmune Inc.

Poster: Pemvidutide Treatment Results in Concurrent Reductions in[...]
CRISPR Therapeutics AG

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel[...]
Altimmune Inc.

Poster: Gastrointestinal Tolerability of Pemvidutide Without Dose[...]

Economy, Business and Finance

Altimmune Inc.

11/08/2026 | Press release | Distributed by Public on 11/08/2026 15:34

Presentation: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the[...]

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Altimmune Inc. published this content on November 08, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 08, 2026 at 21:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]